TY - JOUR
T1 - Genetic subtypes of familial hemophagocytic lymphohistiocytosis
T2 - Correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions
AU - Ishii, Eiichi
AU - Ueda, Ikuyo
AU - Shirakawa, Ryutaro
AU - Yamamoto, Ken
AU - Horiuchi, Hisanori
AU - Ohga, Shouichi
AU - Furuno, Kenji
AU - Morimoto, Akira
AU - Imayoshi, Miyoko
AU - Ogata, Yoshiyasu
AU - Zaitsu, Masafumi
AU - Sako, Masahiro
AU - Koike, Kenichi
AU - Sakata, Akifumi
AU - Takada, Hidetoshi
AU - Hara, Toshiro
AU - Imashuku, Shinsaku
AU - Sasazuki, Takehiko
AU - Yasukawa, Masaki
PY - 2005/5/1
Y1 - 2005/5/1
N2 - Mutations of the perforin (PRF1) and MUNC13-4 genes distinguish 2 forms of familial hemophagocytic lymphohistiocytosis (FHL2 and FHL3, respectively), but the clinical and biologic correlates of these genotypes remain in question. We studied the presenting features and cytotoxic T lymphocyte/natural killer (CTL/NK) cell functions of 35 patients for their relationship to distinct FHL subtypes. FHL2 (n = 11) had an earlier onset than either FHL3 (n = 8) or the non-FHL2/FHL3 subtype lacking a PRF1 or MUNC13-4 mutation (n = 16). Deficient NK cell activity persisted after chemotherapy in all cases of FHL2, whereas some patients with FHL3 or the non-FHL2/FHL3 subtype showed partial recovery of this activity during remission. Alloantigen-specific CTL-mediated cytotoxicity was deficient in FHL2 patients with PRF1 nonsense mutations, was very low in FHL3 patients, but was only moderately reduced in FHL2 patients with PRF1 missense mutations. These findings correlated well with Western blot analyses showing an absence of perforin in FHL2 cases with PRF1 nonsense mutations and of MUNC13-4 in FHL3 cases, whereas in FHL2 cases with PRF1 missense mutations, mature perforin was present in low amounts. These results suggest an association between the type of genetic mutation in FHL cases and the magnitude of CTL cytolytic activity and age at onset.
AB - Mutations of the perforin (PRF1) and MUNC13-4 genes distinguish 2 forms of familial hemophagocytic lymphohistiocytosis (FHL2 and FHL3, respectively), but the clinical and biologic correlates of these genotypes remain in question. We studied the presenting features and cytotoxic T lymphocyte/natural killer (CTL/NK) cell functions of 35 patients for their relationship to distinct FHL subtypes. FHL2 (n = 11) had an earlier onset than either FHL3 (n = 8) or the non-FHL2/FHL3 subtype lacking a PRF1 or MUNC13-4 mutation (n = 16). Deficient NK cell activity persisted after chemotherapy in all cases of FHL2, whereas some patients with FHL3 or the non-FHL2/FHL3 subtype showed partial recovery of this activity during remission. Alloantigen-specific CTL-mediated cytotoxicity was deficient in FHL2 patients with PRF1 nonsense mutations, was very low in FHL3 patients, but was only moderately reduced in FHL2 patients with PRF1 missense mutations. These findings correlated well with Western blot analyses showing an absence of perforin in FHL2 cases with PRF1 nonsense mutations and of MUNC13-4 in FHL3 cases, whereas in FHL2 cases with PRF1 missense mutations, mature perforin was present in low amounts. These results suggest an association between the type of genetic mutation in FHL cases and the magnitude of CTL cytolytic activity and age at onset.
UR - http://www.scopus.com/inward/record.url?scp=20944449435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20944449435&partnerID=8YFLogxK
U2 - 10.1182/blood-2004-08-3296
DO - 10.1182/blood-2004-08-3296
M3 - Article
C2 - 15632205
AN - SCOPUS:20944449435
SN - 0006-4971
VL - 105
SP - 3442
EP - 3448
JO - Blood
JF - Blood
IS - 9
ER -